Clinical Trial Search

Primary: Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1. — 15.4; 20.0; 0 percentage of participants…

Primary: Change in Cellular Granular Osmiophilic Deposits (GRODs) in Electron Micrographs of Peripheral White Blood Cells. — -0.3317 Average number of GRODs

Primary: Maximum Increase of Troponin at 24 Hours — 0.478; 0.476 ng/ml

Primary: To Determine the Optimal Regimen of Post-graft Immunosuppression With High-dose Cy Following Fludarabine, Busulfan, and Transplantation of Fully HLA-matched Bone Marrow…

Primary: Median GC Dose Taken During the Noninterventional Phase — 6; 6; 4; 0 mg

Primary: Change in 1-repetition Maximum (RM) Muscle Strength (Leg Press, Paretic Side) — 126.1; 11.3 lbs

Primary: Days of Sobriety in First 90 Days — 87.3; 84.64 Days of Sobriety — p=.55

Primary: Pain During the Pelvic Floor Examination — 0.4; 0.9; 1.3; 3.6 units on Wong Baker pain scale

Primary: Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28 — 0.885; 1.002; 1.002 percentage — p=0.5403

Primary: Change in Percent Excess Weight — -45.7; -50.8; -47.7; -46.5 percentage of excess weight lost

Primary: Subjective Sleepiness — 11.8; 10.2; 9.9 units on a scale

Primary: Change From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Patient — -4.4; -4.6; -4.9 scores on a scale…

Primary: Annual Rate of Change in Lung Density — -1.50; -2.12; -1.45; -2.19 g/L per year — p=0.029

Primary: Cohort 1: Determination of Rest Dose: Dose Acquistion Time Product — 100 MBq X Minutes

Primary: Number of Participants Who Are Lice Free at All Follow-up Visits (Day 1, 7 and 14) Through the Day 14 Visit — 31; 42; 11 participants — p=<0.001